Biosynthesis of 2-aminooctanoic acid and its use to terminally modify a lactoferricin B peptide derivative for improved antimicrobial activity

  • Appl Microbiol Biotechnol. 2018 Jan;102(2):789-799. doi: 10.1007/s00253-017-8655-0.
Sarah A Almahboub  1 Tanja Narancic  1 Marc Devocelle  2 Shane T Kenny  3 William Palmer-Brown  1 Cormac Murphy  1 Jasmina Nikodinovic-Runic  4 Kevin E O'Connor  5  6
Affiliations
  • 1. UCD Earth Institute and School of Biomolecular and Biomedical Science, O'Brien Centre for Science, University College Dublin, Belfield, Dublin 4, Ireland.
  • 2. Centre for Synthesis and Chemical Biology, Department of Pharmaceutical & Medicinal Chemistry, Royal College of Surgeons in Ireland, 123 St Stephens Green, Dublin 2, Ireland.
  • 3. Bioplastech Ltd., Nova UCD, Belfield Innovation Park, University College Dublin, Belfield, Dublin 4, Ireland.
  • 4. Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Vojvode Stepe 444a, Belgrade, Serbia.
  • 5. UCD Earth Institute and School of Biomolecular and Biomedical Science, O'Brien Centre for Science, University College Dublin, Belfield, Dublin 4, Ireland. [email protected].
  • 6. BEACON - Bioeconomy Research Centre, University College Dublin, Belfield, Dublin 4, Ireland. [email protected].
Abstract

Terminal modification of peptides is frequently used to improve their hydrophobicity. While N-terminal modification with fatty acids (lipidation) has been reported previously, C-terminal lipidation is limited as it requires the use of linkers. Here we report the use of a biocatalyst for the production of an unnatural fatty amino acid, (S)-2-aminooctanoic acid (2-AOA) with enantiomeric excess > 98% ee and the subsequent use of 2-AOA to modify and improve the activity of an antimicrobial peptide. A transaminase originating from Chromobacterium violaceum was employed with a conversion efficiency 52-80% depending on the ratio of amino group donor to acceptor. 2-AOA is a fatty acid with amino functionality, which allowed direct C- and N-terminal conjugation respectively to an antimicrobial peptide (AMP) derived from lactoferricin B. The Antibacterial activity of the modified peptides was improved by up to 16-fold. Furthermore, minimal inhibitory concentrations (MIC) of C-terminally modified peptide were always lower than N-terminally conjugated peptides. The C-terminally modified peptide exhibited MIC values of 25 μg/ml for Escherichia coli, 50 μg/ml for Bacillus subtilis, 100 μg/ml for Salmonella typhimurium, 200 μg/ml for Pseudomonas aeruginosa and 400 μg/ml for Staphylococcus aureus. The C-terminally modified peptide was the only peptide tested that showed complete inhibition of growth of S. aureus.

Keywords
2-aminooctanoic acid; Antimicrobial peptide; Chromobacterium violaceum DSM30191; Unnatural amino acids; ω-Transaminase.
Products